Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Close this search box.


Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Ensuring high-quality iPSCs to maximize drug discovery success

Learn the rigorous measures established at Syngene for tissue procurement, iPSC reprogramming, systematic cell banking, inventory management, and quality control of every iPSC batch to maximize drug discovery success.

Establishing the simple complex: Route to a successful large molecule bioanalytical sample analysis

Learn the simple and complex connections that must be established for successful large molecule bioanalytical sample analysis supporting clinical trials.

Navigating a smarter race: Lead to first-in-human studies

Learn the key strategies adopted by leading CDMO Syngene to accelerate the lead to first-in-human (FIH) journey of small molecules for clients.

Detection and quantitation of process-related impurities in biopharma manufacturing

Learn the challenges in the detection and quantitation of process-related impurities, including nitrosamine and azido impurities, and Syngene’s capabilities and solutions to resolve them.

Holistic, mechanism-driven approach to toxicity assessment using Computational and Data Sciences

Learn how Syngene provides in silico and in vitro support for holistic toxicity assessment using Computational & Data Sciences.

Regulatory role of Biophysics in Biologics CMC

Learn the role of biophysics-driven analytical tools in accurately identifying biologics CQAs and analyzing HOS to make the final product efficacious and safe for patients from a regulatory perspective.

Choosing the ‘right’ CRO-CDMO in Biopharma - What has changed

Learn the new criteria that have emerged as more important for selecting an outsourcing partner consequent to disruptions caused by the COVID-19 pandemic.

How Syngene is implementing Green Chemistry in pharmaceutical development – Design to Delivery

Learn how Syngene is helping pharma companies minimize environmental impact using its Green Chemistry approach to drug development.

Transforming Supply Chain risks into a competitive advantage in the CRO-CDMO space-The Syngene story

Learn how Syngene built a biopharma supply chain that is fast, resilient, and future-proof and, in the process, turned supply chain risks into a competitive advantage.

Intensified Biomanufacturing

Learn how Syngene is achieving three to four-fold higher titers of mAbs using its Intensified Fed-Batch process

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details